Cg Oncology, Inc.
Clinical trials sponsored by Cg Oncology, Inc., explained in plain language.
-
New hope for bladder cancer patients: virus therapy targets tumors when standard treatment fails
Disease control OngoingThis study tests a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not get better after standard therapy (BCG). The treatment uses a modified virus to attack cancer cells. About 190 adults will take part …
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
Bladder cancer virus therapy shows promise in preventing recurrence
Disease control OngoingThis study tests a new treatment called cretostimogene grenadenorepvec, a virus that targets cancer cells, to see if it can keep intermediate-risk bladder cancer from returning after surgery. About 367 people will be randomly assigned to receive the virus or just be watched. The …
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
Bladder cancer virus therapy study pulled before starting
Disease control TerminatedThis study aimed to test a virus-based treatment called CG0070 for people with a high-grade bladder cancer that hadn't spread into muscle. It was for patients whose cancer came back after standard therapy (BCG) and who chose not to have their bladder removed. The study was withdr…
Phase: PHASE2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC